Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Ariad Pharmaceuticals Inc.
DescriptionOral tyrosine kinase inhibitor targeting EGFR and HER2 mutations
Molecular Target Epidermal growth factor receptor (EGFR) ; Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of Action 
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I/II
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat non-small cell lung cancer (NSCLC); Treat non-small cell lung cancer (NSCLC) patients with specific mutations in EGFR or HER2
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today